Recent Analysts’ Ratings Changes for Alphatec (ATEC)

Alphatec (NASDAQ: ATEC) has recently received a number of price target changes and ratings updates:

  • 11/13/2026 – Alphatec was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
  • 11/13/2026 – Alphatec had its price target lowered by HC Wainwright from $24.00 to $20.00. They now have a “buy” rating on the stock.
  • 11/4/2026 – Alphatec was downgraded by UBS Group from “buy” to “neutral”. They now have a $8.50 price target on the stock, down from $15.00.
  • 10/30/2026 – Alphatec had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 10/30/2026 – Alphatec had its price target lowered by TD Cowen from $13.00 to $10.00. They now have a “buy” rating on the stock.
  • 10/30/2026 – Alphatec had its price target lowered by Needham & Company LLC from $14.00 to $12.00. They now have a “buy” rating on the stock.
  • 10/30/2026 – Alphatec had its price target lowered by Canaccord Genuity Group from $19.00 to $16.00. They now have a “buy” rating on the stock.
  • 10/30/2026 – Alphatec had its price target lowered by JPMorgan Chase & Co. from $16.00 to $15.00. They now have an “overweight” rating on the stock.
  • 10/30/2026 – Alphatec had its price target lowered by Wells Fargo & Company from $14.00 to $12.00. They now have an “overweight” rating on the stock.
  • 10/30/2026 – Alphatec was downgraded by BMO Capital Markets from “outperform” to “market perform”. They now have a $8.00 price target on the stock.
  • 10/11/2026 – Alphatec was downgraded by Wall Street Zen from “buy” to “hold”.
  • 10/3/2026 – Alphatec was upgraded by Wall Street Zen from “hold” to “buy”.

Alphatec Stock Performance

Alphatec stock opened at $7.07 on Monday. The stock has a market cap of $1.10 billion, a price-to-earnings ratio of -12.85 and a beta of 0.88. The company’s 50-day moving average price is $9.75 and its two-hundred day moving average price is $10.17. Alphatec Holdings, Inc. has a 52 week low of $6.81 and a 52 week high of $23.29.

Alphatec (NASDAQ:ATEC – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The medical technology company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). The company had revenue of $221.17 million during the quarter, compared to analyst estimates of $225.16 million. Alphatec had a negative return on equity of 6,752.24% and a negative net margin of 10.35%. The company’s revenue was up 12.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.03 earnings per share. Research analysts expect that Alphatec Holdings, Inc. will post -0.40 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director David M. Demski purchased 60,000 shares of the firm’s stock in a transaction on Friday, October 30th. The stock was purchased at an average cost of $6.81 per share, with a total value of $408,600.00. Following the purchase, the director owned 491,635 shares in the company, valued at $3,348,034.35. This trade represents a 13.90% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick Miles purchased 115,000 shares of the firm’s stock in a transaction on Thursday, September 10th. The shares were purchased at an average cost of $8.81 per share, with a total value of $1,013,150.00. Following the completion of the purchase, the chief executive officer owned 5,893,551 shares in the company, valued at $51,922,184.31. This represents a 1.99% increase in their position. The disclosure for this purchase is available in the SEC filing. 13.48% of the stock is owned by company insiders.

Alphatec Holdings, Inc. is a medical technology company focused on developing and marketing products for spine surgery. Its offerings are intended to support the surgical treatment of spinal disorders and include implants, biologics, instruments and access systems, along with technologies designed to assist surgeons during procedures. The company’s product portfolio includes solutions for several surgical approaches and stages of spine care, including systems for planning, accessing and instrumenting the spine.

Featured Articles

Receive News & Ratings for Alphatec Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.